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Abstract
A systematic review and network meta-analysis were conducted to compare the clinical efﬁcacy of
immunomodulatory drug-containing regimens in patients with relapsed or refractory multiple myeloma.
Daratumumab plus lenalidomide and dexamethasone had a signiﬁcant advantage in improving progression-
free survival of patients compared with other immunomodulatory drug-containing regimens.
Background: Previous network meta-analyses combined studies of immunomodulatory drug (IMiD)econtaining and
IMiD-free regimens, despite a lack of head-to-head randomized controlled trials to robustly link them. However, pa-
tients with relapsed or refractory multiple myeloma (RRMM) treated with IMiD-containing regimens differ from those
treated with IMiD-free regimens, especially relating to treatment history, which is an important treatment-effect
modiﬁer requiring clinical consideration when evaluating the most appropriate subsequent treatment options. A
need exists to separately assess the efﬁcacy of treatment regimens for patients who are suitable candidates for IMiD-
containing and IMiD-free regimens. The presented analyses will enable clinicians to assess the best regimens to use in
patients suitable for IMiD-containing regimens. Materials and Methods: We used a Bayesian network meta-analysis
to compare IMiD-containing regimens in patients with RRMM. Additionally, subgroup analyses were conducted
stratiﬁed by previous therapy line, previous bortezomib therapy, and previous lenalidomide therapy. Results: The
results indicated that triplet combinations are more effective than doublet combinations. Of the triplet combinations,
daratumumab, lenalidomide, dexamethasone (DRd) was signiﬁcantly better in improving progression-free survival in
patients with RRMM than were other IMiD-containing regimens (lenalidomide, dexamethasone [Rd]: hazard ratio [HR],
0.37; carﬁlzomib, Rd: HR, 0.54; elotuzumab, Rd: HR, 0.54; ixazomib, Rd: HR, 0.50). Similar trends were observed for
overall survival and overall response. DRd showed the greatest probability of being the best treatment for all clinical
efﬁcacy outcomes. The subgroup analyses results were consistent with the base-case results. Conclusion: In patients
with RRMM who are suitable for an IMiD-containing regimen, DRd showed clear advantages in survival and response
outcomes compared with other IMiD-containing regimens.
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Efﬁcacy of IMiD Regimens for RRMMIntroduction This approach could have introduced a potential for bias, because
Multiple myeloma (MM) is an incurable, debilitating disease that
accounts for 1% of deaths across all age groups.1 Because most
patients with MM will relapse or develop disease that does not
respond to therapy, relapsed or refractory MM (RRMM) also
constitutes a major health burden, with an unmet need regarding
progressive disease symptoms and treatment-related complications.
Clinicians consider a number of factors before assigning RRMM
patients to a speciﬁc treatment regimen, including the patient’s pre-
vious drug exposure and regimen-related toxicity.2 Previous studies of
RRMM have reported that therapeutic outcomes correlate with both
the nature and the number of treatment lines to which patients have
previously been exposed. For example, Kumar et al3 found that out-
comes deteriorate once a patient’s disease has become refractory to
previous treatments. These ﬁndings suggest that characteristics of
previous therapy are important treatment-effect modiﬁers to consider
when evaluating the most suitable regimens for patients with RRMM.
If a patient was previously treated with proteasome inhibitors and
their disease continues to progress, current clinical practice suggests
a switch in drug class to immunomodulatory drug (IMiD)-con-
taining regimens.4 New drugs, such as carﬁlzomib, elotuzumab,
ixazomib, and daratumumab, have recently been developed to use
in combination with lenalidomide plus dexamethasone (Rd) for
treatment of patients with RRMM. To best serve patients’ interests
in this and other settings in which such a regimen is a suitable
choice, clinicians require an evidence-based understanding of how
the various Rd treatment options compare with respect to the
treatment response and effects on survival.
Previous network meta-analyses (NMAs) combined studies of
IMiD-containing and IMiD-free regimens, despite a lack of head-to-
head randomized controlled trials (RCTs) to robustly link them.5-7Table 1 PICOS-T Criteria
Variable Inclusion Criteria
SLR criteria
Population Adult patients with primary diagnosis of RRM
Intervention/comparators Studies that compared  2 licensed treatments t
considered relevant comparators in RRMM, including
undergoing or being prepared for regulatory body p
review, already licensed, or routinely used
Outcomes PFS, OS, ORR
Study design Phase II or III RCTs
Time point Publications indexed in literature databases since
material from key conferences from 2013 to
Criteria added to NMA
Population Trials with similar study design (ie, patients with rela
refractory disease randomized to treatmen
Intervention/comparators Studies that compared  2 active IMiD-containing
and studies with a common comparator in the n
Outcomes PFS and OS: HRs or KM graphs; ORR: number/per
patients achieving a response
Abbreviations: HR ¼ hazard ratio; IFN-a ¼ interferon-a; IMiD ¼ immunomodulatory drug; KM ¼ Kap
PFS ¼ progression-free survival; PICOS-T ¼ population, interventions, comparators, outcomes, stud
multiple myeloma; SLR ¼ systematic literature review.
Clinical Lymphoma, Myeloma & Leukemia March 2018it assumes that all treatment choices for RRMM are equally appli-
cable, regardless of the patient’s treatment history and other factors
that determine the appropriateness of a particular option. Analyses of
such combined networks also require further assumptions to link
evidence networks that differ fundamentally with regard to their
patient populations and the clinical questions investigated. Given the
resulting uncertainty surrounding the ﬁndings of NMAs to date, a
current unmet need exists with regard to deciding among the IMiD-
based regimens for patients for whom such a treatment is appropriate.
The objective of the present study was to use an NMA to compare
IMiD-based combination regimens for patients with RRMM.
Materials and Methods
Systematic Literature Review
A systematic literature review (SLR) was conducted to identify
RCTs reporting efﬁcacy outcome data for patients with RRMM.
Indexed databases were searched to identify studies reported in
English from January 1, 1995 to November 3, 2016. The strategies
used in the database searches are provided in the Supplemental
Tables (available in the online version). In addition, the pro-
ceedings from key conferences from January 2013 to November
2016 were reviewed for relevant meeting abstracts that met the
eligibility criteria. The references of the SLRs and meta-analyses
identiﬁed by the search were manually reviewed for any additional
relevant studies that were not identiﬁed by the searches. Also,
documents from the European Medicines Agency and US Food and
Drug Administration were checked for any missing data. The SLR
adhered to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses statement guidelines8 and followed the study
protocol developed for the present review.Exclusion Criteria
M Patients without primary diagnosis of RRMM
hat were
treatments
relicensing
Studies examining efﬁcacy of IFN-a, conditioning chemotherapy
to prepare for stem cell transplantation, maintenance therapy,
preferred sequence of treatments, and treatments aimed at
managing complications of RRMM
Data that cannot be extracted
Single-arm trials and noninterventional studies
1995 and
2016
Publications indexed in or before 1994; conference abstracts
presented in or before 2012
psed and/or
t)
Studies of patients who had responded to initial treatment in a
prerandomized phase and were then randomized to treatment
regimens
etwork
Studies that only compared different regimens of the same active
drug or compared dose escalations of the same drug; studies
assessing treatments that could not be indirectly compared with
treatments in the network; and studies that did not have a
comparator common to other studies included in the network
centage of Data required for NMA not available
lan-Meier; NMA ¼ network meta-analysis; ORR ¼ overall response rate; OS ¼ overall survival;
y design, and time point; RCT ¼ randomized controlled trial; RRMM ¼ relapsed or refractory
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses Flowchart for Study Selection and Review. aThe
Cochrane Library includes Cochrane reviews, a database of abstracts of reviews of effects, the Cochrane Central Register of
Controlled Trials, and the National Health Services Economic Evaluation Database. bConference searches included American
Society of Clinical Oncology, American Society of Hematology, European Hematology Association, International Myeloma
Working Group, and International Society for Pharmacoeconomics and Outcomes Research
Abbreviations: MA ¼ meta-analysis; NMA ¼ network meta-analysis; PI ¼ proteasome inhibitor; RCT ¼ randomized controlled trial; RRMM ¼ relapsed or refractory multiple myeloma; SLR ¼
systematic literature review.
Meletios Athanasios Dimopoulos et alEligibility Criteria. Studies were selected for inclusion in the
present review using the population, interventions, comparators,
outcomes, study design, and time point (PICOS-T) criteria
outlined in Table 1.Study Selection. All abstracts and full-text articles were screened by
2 independent investigators, and any conﬂicting screening decisions
were resolved by a third investigator. Articles reporting studies
meeting the inclusion criteria and none of the exclusion criteria wereClinical Lymphoma, Myeloma & Leukemia March 2018 - 165
Figure 2 Network Diagram. Brown indicates glucocorticoid alone; blue, proteasome inhibitor alone or combined; green,
immunomodulators with or without a glucocorticoid; gray, immunomodulators and glucocorticoid with or without an
alkylating agent; orange, monoclonal antibody alone or combined; bold text, treatments licensed by the US Food and Drug
Administration and/or European Medicines Agency; regular text, unlicensed treatments; black dashed lines, trials with
incomplete or interim results; and solid red lines, trials removed from the base-case network meta-analysis
Abbreviations: d ¼ dexamethasone; DRd ¼ daratumumab, lenalidomide, dexamethasone; ERd ¼ elotuzumab, lenalidomide, dexamethasone; ICd ¼ pomalidomide, cyclophosphamide,
dexamethasone; Id ¼ pomalidomide, dexamethasone; KRd ¼ carﬁlzomib, lenalidomide, dexamethasone; NRd ¼ ixazomib, lenalidomide, dexamethasone; Rd ¼ lenalidomide, dexamethasone.
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explore whether the studies could be included in the NMA (Table 1).
Data Collection and Quality Assessment. The study characteristics,
patient characteristics, treatment details, and efﬁcacy outcomes were
extracted by 1 investigator (MR or YX) and validated by a second
investigator (MR or YX). Any discrepancies between the 2 in-
vestigators were resolved by a third investigator (KF). The following
clinical efﬁcacy data were extracted: hazard ratios (HRs), including
95% conﬁdence intervals for progression-free survival (PFS), overall
survival (OS), and the proportion of patients with an overall
response (overall response rate). When the HRs had not been re-
ported, these data were imputed from the Kaplan-Meier curves for
PFS and/or OS presented in the reports.
The quality of the included full-text studies was assessed using
the checklist described in the Centre for Reviews and Dissemination
guidance document,9 with each trial assigned an overall quality
rating of high, moderate, or low.
Geometry of the Network. RCTs were included in the network only
if they had  2 arms that allowed the formation of a network of
IMiD-containing regimens, regardless of drug class or mechanism of
action (additional inclusion criteria for the studies included in the
NMA are listed in Table 1). RCTs comparing different administra-
tion routes, doses, or schedules of a speciﬁc regimen were excluded.
An assessment was undertaken to determine the feasibility of
conducting an NMA of the efﬁcacy outcomes in the identiﬁedClinical Lymphoma, Myeloma & Leukemia March 2018RCTs. The feasibility assessment included a comparison of patient
population similarity (eg, number of previous lines of therapy and
previous treatment criteria) and intervention similarity (eg, treat-
ment dosing and administration). This included eliciting views from
key opinion leaders and clinical experts from North and South
America and Europe using an advisory board meeting on the patient
eligibility criteria across RCTs.
Analysis
The NMA combined direct and indirect estimates of the relative
treatment effect in a single analysis. Speciﬁcally, all analyses were
conducted within a Bayesian framework using OpenBUGS, version
3.2.2 software.10 The NMA involved a 50,000 run-in iteration
phase for parameter estimation. Because of the limitations of the
network (ie, the presence of only 1 study per treatment compari-
son), only ﬁxed-effects models were ﬁtted. Because only 1 study was
present per comparison, it was not possible to test for statistical
heterogeneity or inconsistency in effects. To provide hierarchy
probabilities, the analysis used ranking probabilities and surface
under the cumulative ranking curve, which provides the cumulative
ranking (the probability of being that rank or higher) for each
treatment assessed.
The output of the NMA included the following:
 Point estimates: HRs for OS and PFS, and odds ratios (ORs) for
overall response, with credible intervals (CrIs)
 Bayesian pairwise probability for the treatment of interest being
more effective than the other comparators assessed in the
Table 2 Study and Patient Characteristics From RCTs Included in NMA
Trial
Intervention (Dosage);
Patients, n Outcomes
Median (Range)
LOT at Baseline Previous Treatment Criteria
Previous Treatment
Exposure at Baseline Relapsed/Refractory Status
Base-Case Analyses
ASPIRE15 Carﬁlzomib (20-27 mg/m2) þ
lenalidomide (25 mg) þ
dexamethasone (40 mg); 396
PFS: HR, KM; OS:
HR, KM; ORR: sCR, CR,
and VGPR
2 (1-3) Excluding bortezomib or
lenalidomide þ dexamethasone
refractory; previous carﬁlzomib
Bortezomib, 66%; lenalidomide, 20%;
IMiD, 59%; bortezomib þ IMiD, 37%
Bortezomib nonresponsive, 15%;
lenalidomide refractory, 7%; IMiD refractory,
22%; bortezomib nonresponsive and IMiD
refractory, 6%
Lenalidomide (25 mg) þ
dexamethasone (40 mg); 396
2 (1-3) Bortezomib: 66%
lenalidomide: 20%
IMiD: 58%
bortezomib þ IMiD: 35%
Bortezomib nonresponsive, 15%;
lenalidomide refractory, 7%; IMiD refractory,
22%; bortezomib nonresponsive and IMiD
refractory, 7%
ELOQUENT-217 Elotuzumab (10 mg/kg) þ
lenalidomide (25 mg) þ
dexamethasone (40 mg); 321
PFS: HR, KM; OS: HRa,b;
ORR: sCR, CR, VGPR,
and PR
2 (1-4) Including lenalidomide  10%
of study sample; excluding
lenalidomide refractory
Bortezomib, 68%; thalidomide, 48%;
lenalidomide, 5%
Bortezomib refractory, 22%; thalidomide
refractory, 9%
Lenalidomide (25 mg) þ
dexamethasone (40 mg); 325
2 (1-4) Bortezomib, 71%; thalidomide, 48%;
lenalidomide, 6%
Bortezomib refractory, 21%
thalidomide refractory: 11%
POLLUX16 Daratumumab (16 mg/kg) þ
lenalidomide (25 mg) þ
dexamethasone (40 mg); 286
PFS: HRa; OS: HRa; ORR:
sCR, CR, VGPR, and PR
1 (1-11) Excluding allogeneic SCT;
lenalidomide refractory
PI, 86%; bortezomib, 84%; carﬁlzomib,
2%; IMiD, 55%; lenalidomide, 18%;
thalidomide, 43%
PI refractory, 16%; IMiD refractory, 4%;
PI þ IMiD refractory, 5%; bortezomib
refractory, 21%; carﬁlzomib refractory;
1%; thalidomide refractory, 9%
Lenalidomide (25 mg) þ
dexamethasone (40 mg); 283
1 (1-8) PI, 86%; bortezomib, 84%; carﬁlzomib,
2%; IMiD, 55%; lenalidomide, 18%;
thalidomide, 44%
PI refractory, 20%; IMiD refractory, 4%;
PI þ IMiD refractory, 2%; bortezomib
refractory, 21%; carﬁlzomib refractory,
1%; pomalidomide refractory, 0.7%;
thalidomide refractory, 6%
Tourmaline-MM118 Ixazomib (4 mg) þ lenalidomide
(25 mg) þ dexamethasone
(40 mg); 360
PFS: HR, KMc; OS: a,d;
ORR: sCR, CR, VGPR,
and PR
Mean, 1.5 (1-3) Including thalidomide refractory;
excluding PI, lenalidomide
refractory
Bortezomib, 69%; carﬁlzomib, < 1%;
lenalidomide, 12%; thalidomide, 44%
PI refractory, 1%; IMiD refractory, 21%
Lenalidomide (25 mg) þ
dexamethasone (40 mg); 362
Mean, 1.5 (1-3) Bortezomib, 69%; carﬁlzomib, 1%;
lenalidomide, 12%; thalidomide, 47%
PI refractory, 2%; IMiD refractory, 25%
Sensitivity Analyses
MM-00313 Pomalidomide (4 mg) þ
dexamethasone (40 mg); 302
PFS: HR, KM; OS: HR,
KM; ORR: e
5 (2-17) Including  2 cycles of
lenalidomide and/or bortezomib;
previous alkylator; excluding
thalidomide, lenalidomide,
dexamethasone hypersensitivity;
high-dose dexamethasone
resistance
ASCT, 69%-71%; bortezomib, 100%;
dexamethasone, 98%-99%;
lenalidomide, 100%; thalidomide,
57%-61%
Bortezomib refractory, 79%; lenalidomide
refractory, 92%-95%; bortezomib and
lenalidomide refractory, 74%-75%
Dexamethasone (40 mg); 153
MM-00912,14 Lenalidomide (25 mg) þ
dexamethasone (40 mg); 177
PFS: f; OS: HR, KM;
ORR: e
1 previous LOT,
38%;  2 previous
LOTs, 62%
NR Bortezomib, 11%; SCT, 62%;
thalidomide, 44%
NR
Dexamethasone (40 mg); 176
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represented as 100% probability)
 The probability that each treatment ranked in a certain order
within the network for each outcome provided; rank probabili-
ties were determined by the location, spread, and overlap of the
posterior distributions of the relative treatment effects
When interpreting the analysis ﬁndings, a 95% CrI that does not
cross the value of 1.00 (for an HR and OR) indicates a treatment
can be considered more effective than its comparator (equivalent to
a Bayesian pairwise probability of P  97.5%).
Subgroup Analyses
Subgroup analyses for PFS were conducted to conﬁrm the
robustness of the results from the base-case analysis by exploring the
effect of the clinically meaningful treatment-effect modiﬁers. The
speciﬁc analyses included stratiﬁcation by previous line of therapy
(LOT; 1 previous LOT or  2 previous LOTs), patients with and
without previous bortezomib exposure, and patients with and
without previous lenalidomide exposure.
Results
Study Selection
The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses ﬂowchart of RCT selection is shown in Figure 1. The
indexed database searches yielded 2161 citations, and an additional
85 meeting abstracts were identiﬁed. After removal of the duplicate
reports indexed in > 1 database, 1583 unique abstracts were
screened, of which 285 full-text articles and conference proceedings
were considered for full review. Of these, 203 were excluded: 96 did
not meet the SLR inclusion criteria and 107 did not meet the NMA
criteria. The remaining 82 studies reported on 8 RCTs, which were
included in the NMA. Further details about the RCTs excluded
because of the NMA criteria are included in the Supplemental
Tables (available in the online version).
Summary of Network Geometry
Eight identiﬁed studies were included in the network (Figure 2).
However, 4 of these trials11-14 were excluded from the subsequent
base-case analyses because their patient populations differed
substantially from those of the other studies (eg, different treatment
history; ie,  2 previous LOTs) or had included an irrelevant
comparator not routinely used in clinical practice (eg, dexametha-
sone monotherapy). However, these trials were included in the
sensitivity analyses. The results from the base-case analyses are
included in the present report; the results from the sensitivity an-
alyses are included in the Supplemental Tables (available in the
online version).
The base-case network included 4 trials evaluating carﬁlzomib
plus Rd (KRd),15 daratumumab plus Rd (DRd),16 elotuzumab
plus Rd (ERd),17 and ixazomib plus Rd (NRd),18 with Rd being
the reference treatment. All trials in the base-case analysis had
included patients who had received  1 previous LOT; 3 of the
studies had included only patients who had received  3 previous
LOTs. All base-case trials had the same dosing and administration
of Rd. Finally, all base-case trials had excluded patients with dis-
ease refractory to lenalidomide.
Figure 3 (A) Progression-Free Survival, (B) Overall Survival, and (C) Overall Response Rate With Immunomodulatory Drug
(IMiD)-containing Regimens. Hazard ratios for a given treatment compared with another IMiD-containing regimen presented
for (A) progression-free survival and (B) overall survival. (C) Comparisons for each treatment versus each of the other
treatments; speciﬁcally, every combination of A versus B, where A is the treatment at the beginning of each row and B is the
treatment at the top of each column. Odds ratios (ORs) > 1 indicate a numerical advantage for the treatment at the end of the
row. To obtain ORs for comparisons in the opposite direction, reciprocals should be taken. The probability (prob) that the OR
for A versus B is < 1 (ie, that regimen A is more Efﬁcacious) is presented under the OR. Interventions with a signiﬁcant
advantage are shown in bold with green shading; interventions with a trend toward improving the overall response (eg, OR >
1.20 but credible intervals crossing 1.0) are shaded in orange. It is possible that 100% probability will appear to represent
any value > 99.951%
Abbreviations: DRd ¼ daratumumab, lenalidomide, dexamethasone; ERd ¼ elotuzumab, lenalidomide, dexamethasone; KRd ¼ carﬁlzomib, lenalidomide, dexamethasone; NRd ¼ ixazomib,
lenalidomide, dexamethasone; Rd ¼ lenalidomide, dexamethasone.
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Figure 4 Probability of Being the Best Treatment Across Survival and Response Outcomes
Abbreviations: DRd ¼ daratumumab, lenalidomide, dexamethasone; ERd ¼ elotuzumab, lenalidomide, dexamethasone; KRd ¼ carﬁlzomib, lenalidomide, dexamethasone; NRd ¼ ixazomib, lena-
lidomide, dexamethasone; ORR ¼ overall response rate; OS ¼ overall survival; PFS ¼ progression-free survival; Rd ¼ lenalidomide, dexamethasone.
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170 -The sensitivity analyses included 4 trials evaluating dexametha-
sone,12,14 pomalidomide plus dexamethasone,13 and pomalidomide
plus cyclophosphamide and dexamethasone.11 Two of these trials
examined patients who had received  2 previous LOTs and,
accordingly, were not included in the base-case analysis. The
remaining 2 trials in the sensitivity analysis involved patients with 1
LOT but were not a part of the base-case analysis owing the inclusion
of an irrelevant comparator (dexamethasone monotherapy) that was
no longer needed to form a bridge between DRd and pomalidomide
plus dexamethasone once the other 2 trials had been excluded. In
addition, 2 of the trials in the sensitivity analyses required participants
to have disease refractory to lenalidomide11,13 or bortezomib,13
resulting in a large proportion of patients with disease refractory to
lenalidomide and bortezomib compared with the rest of the studies in
the base-case analysis. Finally, 2 studies comparing dexamethasone to
Rd12,14 presented with heterogeneity related to the patients’ Inter-
national Staging System (ISS) stage and also allowed for crossover
between treatment arms, which could have affected the OS estimate.
A summary of the patient populations is presented in Table 2.
The primary reports of the trials included in the base-case analysis
were of moderate quality. The quality assessment information is
available in the Supplemental Tables (available in the online
version). The individual trial data from the base-case RCTs input
into the NMA are also reported in the Supplemental Tables
(available in the online version).
Synthesis of Results
An analysis using a ﬁxed-effects model showed that DRd had a
signiﬁcant advantage in prolonging PFS (ie, an HR < 0.80 with
CrIs not crossing 1.0) for patients with RRMM compared with
other IMiD-containing regimens (Figure 3A). The probability of
DRd providing better results than its comparator ranged from
99.9% (compared with ERd) to 100% (compared with Rd, KRd,
and NRd). All other comparators (ERd, KRd, and NRd)Clinical Lymphoma, Myeloma & Leukemia March 2018demonstrated a signiﬁcant advantage in prolonging PFS compared
with Rd. The results were inconclusive for the comparison of ERd
to KRd; however, a trend was found for NRd to reduce PFS
compared with KRd and ERd.
A ﬁxed-effects analysis demonstrated that Rd was signiﬁcantly
less effective at extending OS compared with KRd, ERd, and DRd
(Figure 3B). NRd was also less effective in improving OS compared
with KRd and ERd. A trend was found for DRd to increase OS
compared with all comparators.
Patients with RRMM who had received DRd were more likely to
achieve an overall response (ie, demonstrated a statistical advantage,
with an OR > 1.20 and CrIs not crossing 1.0) compared with those
treated with Rd, ERd, and NRd. A trend was seen for DRd to improve
the overall response compared with KRd (Figure 3C). Compared with
ERd and NRd, the patients treated with KRd were more likely to
achieve an overall response, although this advantage was not signiﬁcant.
DRd had the greatest probability of being the best treatment
across all clinical efﬁcacy outcomes compared with the other IMiD-
containing regimens (Figure 4). Rd had zero probability of being the
best treatment for any outcome.
Results of Subgroup Analyses
The results across all subgroup analyses were generally consistent
with the base-case analysis for PFS. For the patients who had
received 1 previous LOT, the likelihood of prolonging PFS wors-
ened for NRd compared with Rd, and the HRs improved in favor of
DRd compared with ERd and NRd (Figure 5A). No signiﬁcant HR
changes were seen for patients who had received  2 previous
LOTs. The HRs were improved in favor of DRd compared with
Rd, KRd, and ERd for patients with no previous bortezomib
therapy (Figure 5B). The HRs remained similar to the base-case
analyses across all comparators for patients who had received pre-
vious bortezomib therapy and for all patients, regardless of whether
they had previously received lenalidomide (Figure 5C). Detailed
Figure 5 Subgroup Analyses: Progression-Free Survival (PFS) of Patients With 1 Versus ‡ 2 Previous Lines of Therapy (LOTs; A), With
and Without Previous Bortezomib Exposure (B), and With and Without Previous Lenalidomide Exposure (C). Tabular data
represent comparisons for each treatment versus each of the other treatments. To obtain hazard ratios (HRs) for
comparisons in the opposite direction, reciprocals should be taken. The probability that the HR is < 1 is presented under the
HR. (A) For 1 previous LOT, HRs < 1 indicate a numerical advantage for the treatment at the top of the column. For ‡ 2
previous LOTs, HRs < 1 indicate a numerical advantage for the treatment at the beginning of the row. (B) For no previous
bortezomib, HRs < 1 indicate a numerical Advantage for the treatment at the top of the column. For previous bortezomib,
HRs < 1 indicate a numerical advantage for the treatment at the beginning of the row. (C) For no previous lenalidomide,
HRs < 1 indicate a numerical advantage for the treatment at the top of the column. For previous lenalidomide, HRs < 1
indicate a numerical advantage for the treatment at the beginning of the row. It is possible that 100% probability will appear
to represent any value > 99.951%. Interventions with a signiﬁcant advantage are shown in bold with green shading;
interventions with a trend toward improving PFS (eg, HR < 0.80 but credible intervals crossing 1.0) are shaded in orange
Abbreviations: DRd ¼ daratumumab, lenalidomide, dexamethasone; ERd ¼ elotuzumab, lenalidomide, dexamethasone; KRd ¼ carﬁlzomib, lenalidomide, dexamethasone; NRd ¼ ixazomib,
lenalidomide, dexamethasone; Rd ¼ lenalidomide, dexamethasone.
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172 -results from the sensitivity analyses are presented in the
Supplemental Tables (available in the online version).
Discussion
Rd-based regimens are 1 of the preferred treatment options for
those RRMM patients for whom IMiD treatment is suitable.19
However, the selection between the available IMiD-containing
options has been complicated by the lack of direct comparative
evidence and that existing NMAs have not sufﬁciently acknowl-
edged the important clinical differences among patients with
different previous treatment exposures. Thus, the present analysis
has offered a more robust approach to estimating the relative effects
of these IMiD-containing interventions.
The key ﬁndings of the analyses include the superiority of DRd
compared with other IMiD-containing regimens for efﬁcacy in
RRMM. These results provide an important context for the
POLLUX study,16 which showed that the addition of dar-
atumumab to Rd signiﬁcantly improved PFS and the overall
response rate and demonstrated a trend toward improved OS,
compared with Rd alone, in patients with RRMM who had
received  1 previous therapy. The results we have presented are
also aligned with recent updates to the National Comprehensive
Cancer Network guidelines, which have recognized DRd as a
category 1 treatment option for previously treated patients with
MM,19 and European Society for Medical Oncology guidelines,
which state that daratumumab triplet combination therapies can
be considered the standard of care, once licensed.20 The ﬁndings
could also help guide the choices that payers and clinicians make
between treatments for second or later LOTs in the treatment of
patients with RRMM.
The patients enrolled in the trials presented in the Rd network in
our analysis had received  1 previous therapy, with a large pro-
portion of these patients having been previously exposed to borte-
zomib and a smaller subset of patients with disease potentially
refractory to bortezomib. In contrast, the trials examining the effect
of IMiD-free regimens generally excluded patients with previous
bortezomib exposure, with some trials further excluding patients
known to have bortezomib-refractory disease. It is clear that the
patients in whom Rd regimens were evaluated differed fundamen-
tally from those in whom IMiD-free regimens were evaluated in
terms of previous drug exposures. Consequently, the trial data for
these patients should be assessed separately in any NMA of RRMM
treatments. Previous NMAs have combined IMiD-containing and
IMiD-free regimens in 1 network for all RRMM patients, with the
assumption that the patient populations were comparable across all
treatment combinations. However, key differences were present in
the treatment exposure across the studies that could have biased the
results of these previous analyses. Further assumptions regarding the
equal efﬁcacy of the comparator treatments were also made.5,6
Despite this, the results of the IMiD-containing network in the
present analysis are consistent with previous NMAs in RRMM,5-7
which have also found DRd to be the best combination of the
currently available treatment options. Thus, regardless of the
different NMA approaches taken between our analysis and previous
reports, daratumumab combined with Rd has consistently been
found to be the most clinically efﬁcacious IMiD-containing
regimen.Clinical Lymphoma, Myeloma & Leukemia March 2018Other important strengths of these analyses should be considered
in the context of other reported NMAs. By separating the Rd reg-
imens into a single network for patients who had received  1
previous LOT and conducting relevant subgroup analyses, these
analyses provided greater opportunities than the other reported
NMAs to eliminate crucial imbalances in treatment-effect modiﬁers
related to previous therapies. In addition, our analysis was limited
only to RCT evidence. Given the lack of a published RCT
providing a head-to-head comparison of IMiD-containing and
IMiD-free regimens, previous NMAs required the use of alternate
types of evidence to connect the networks. Analyzing these networks
separately provided a more robust approach and holds more strongly
to the transitivity and consistency assumptions necessary for the
conduct of a valid and reliable NMA. Furthermore, previous NMAs
were based on an interim analysis of data from the DRd trials. The
present analyses used data from the most recent data-cut of the
POLLUX trial. Another advantage of these analyses was the
exclusion from the base-case analysis of studies with patient pop-
ulations that differed substantially from those of the included
studies (eg, in terms of treatment exposure or previous LOT). This
allowed for the exploration of key potential treatment-effect mod-
iﬁers in sensitivity analyses, the results of which were then used to
validate the results of the base-case analysis.
The present NMA had some limitations. Because each treatment
comparison was informed by a single study only (similar to previous
NMAs), additional analyses controlling for differences in baseline
characteristics using meta-regression techniques were not feasible.
Second, the inclusion of PI-refractory patients in the KRd15 and
NRd18 trials that were included in the base-case network may have
impacted the results in the triplet arms of these studies. Third, OS
can be affected by the subsequent treatment patients receive after
disease progression; however, such data are not available for an
NMA. Thus, the potential OS beneﬁt could not be evaluated while
accounting for such confounding factors. In addition, these analyses
did not consider safety outcomes, focusing instead on the relative
efﬁcacy of the licensed treatments as a key determinant of the
therapeutic choice for RRMM.
Conclusion
The present study has provided a thorough analysis of the
comparative efﬁcacy of IMiD-containing regimens known to
improve response and reduce mortality in patients with RRMM.
Speciﬁcally, the reported NMA results have demonstrated the
value of daratumumab as a treatment option combined with Rd in
this setting, with efﬁcacy advantages compared with other relevant
IMID-containing treatments. In addition, the results from the
subgroup analyses were largely consistent with those from the
base-case analyses. To the best of our knowledge, the present re-
view includes the most comprehensive evidence base available;
therefore, the results can be considered generalizable to the broader
RRMM population for whom an IMiD-containing regimen is
suitable. These ﬁndings provide policymakers and clinicians with
important information regarding the comparative effectiveness of
different IMiD-containing treatment regimens in patients with
RRMM who have received  1 previous LOT. Finally, this
analysis compared only regimens that have been investigated in
clinical trials; therefore, the results are less informative in situations
Meletios Athanasios Dimopoulos et alin which such regimens cannot be used due to prior treatment
exposures, treatment resistance, or reimbursement issues.
Clinical Practice Points
 Previous work has shown a correlation between the number
and type of previous treatment exposure and treatment out-
comes; thus, clinicians must consider a number of factors
before prescribing a speciﬁc treatment regimen for patients
with RRMM.
 Depending on the treatment history and the response to pro-
teasome inhibitors, patients with RRMM might be suitable
candidates for treatment with IMiD-containing regimens.
 The present NMA considered patients suitable for Rd-based
regimens.
 Triplet combinations provided a survival and efﬁcacy advantage
compared with doublet regimens.
 Daratumumab, combined with lenalidomide and dexametha-
sone, provides patients with advantages in survival and response
outcomes compared with other IMiD-containing regimens.
 These ﬁndings align with the recommendation of National
ComprehensiveCancerNetwork andEuropean Society forMedical
Oncology guidelines for daratumumab-containing regimens and
could help guide treatment choices for patients with RRMM.
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Supplemental Table 1 MEDLINE Search Strategy
Search
Search
Criteria Search Algorithm
Search Yield
(March 17, 2016)
Update Search Yield
(November 3, 2016)
1 1 ("Multiple Myeloma"[MeSH] OR ("multiple"[TIAB] AND myelom*[TIAB])
OR "plasma cell myeloma"[TIAB] OR "Kahler’s disease"[TIAB] OR
“Plasmacytoma”[MeSH] OR plasmacytom*[TIAB])
49,858 51,424
2 2 ((relaps*[TIAB] OR refract*[TIAB] OR recurren*[TIAB] OR "resistant"
[TIAB] OR "prior treatment"[TIAB] OR "prior treatments"[TIAB] OR
"prior therapy"[TIAB] OR "prior therapies"[TIAB] OR "previously
treated"[TIAB] OR "second line"[TIAB] OR "third line"[TIAB] OR
"2nd line"[TIAB] OR "3rd line"[TIAB] or "fourth line"[TIAB] OR
"4th line"[TIAB]))
1,002,907 1,043,924
3 3 ("randomized"[TIAB] OR "randomised"[TIAB] OR "controlled
trial"[TIAB] OR "clinical trial"[TIAB] OR "cross over"[tiab] OR
"cross-over"[tiab] OR "crossover"[tiab] OR (doubl* AND blind*[TIAB])
OR (singl* AND blind*[TIAB]) OR ("open"[TIAB] AND label*[TIAB]) OR
"placebo"[TIAB] OR "Clinical Trial" [Publication Type])
1,038,845 1,078,454
4 1 & 2 & 3 1144 1219
5 4 NOT 5 "Animals"[MeSH] NOT "Humans"[MeSH] 1142 1217
6 5 NOT 6 "letter"[PT] OR "editorial"[PT] 1113 1049a
7 6 NOT 7 ((review[pt]) NOT (systematic OR meta-analy* OR ((indirect OR
mixed) AND "treatment comparison")))
975
The limits for this search included only items with abstracts; we also limited the search to exclude animal-only studies (search row 5), letters and editorials (search 6), and nonsystematic reviews
(search 7).
aIn the update search, rows 6 and 7 were combined.
Supplemental Table 2 EMBASE Search Strategy
Search
Search
Criteria Search Algorithm
Search Yield
(March 17, 2016)
Update Search Yield
(November 3, 2016)
1 1 “multiple myeloma”/exp OR (“multiple”:ab,ti AND myelom*:ab,ti) OR
“plasma cell myeloma”:ab,ti OR (kahler*:ab,ti AND “disease”:ab,ti) OR
“plasmacytoma”/exp OR plasmacytom*:ab,ti
72,703 76,064
2 2 relaps*:ab,ti OR refract*:ab,ti OR recurren*:ab,ti OR “resistant”:ab,ti OR
“prior treatment”:ab,ti OR “prior treatments”:ab,ti OR “prior therapy”:ab,ti OR
“prior therapies”:ab,ti OR “previously treated”:ab,ti OR “second line”:ab,ti OR
“third line”:ab,ti OR “2nd line”:ab,ti OR “3rd line”:ab,ti OR “fourth line”:ab,ti
OR “4th line”:ab,ti
1,325,287 1,390,716
3 3 “randomized”:ab,ti OR “randomised”:ab,ti OR “controlled trial”:ab,ti OR
“clinical trial”:ab,ti OR “cross over”:ab,ti OR “crossover”:ab,ti OR
“cross-over”:ab,ti OR (doubl* AND blind*:ab,ti) OR (singl* AND blind*:ab,ti)
OR (“open”:ab,ti AND label*:ab,ti) OR “placebo”:ab,ti
869,396 917,965
4 1 & 2 & 3 1623 1721
5 4 NOT 5 “animal”/exp NOT “human”/exp 1605 1702
6 5 NOT 6 letter:it OR editorial:it OR [conference abstract]/lim OR [conference paper]/lim
OR [conference review]/lim
579 631
7 6 NOT 7 review:it NOT (systematic OR meta AND analy* OR (indirect OR mixed
AND “treatment comparison”))
444 499
The limits for this search included only items with abstracts; we also limited the search to exclude animal-only studies (search 5), letters and editorials and conference abstracts (search 6), and
nonsystematic reviews (search 7).
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Supplemental Table 4 Study and Patient Characteristics From RCTs Excluded From NMA
Trial (Interventions)
Median (Range)
LOT at Baseline
Previous Treatment
Criteria
Previous Treatment
Exposure at Baseline (%) Relapsed/Refractory Status
CA204-009 (EVd vs. Vd) NR Including response to previous
PI regimen; progression on
last regimen; excluding PI
refractory or intolerance
PI: 51%-53% NR
CASTOR (DVd vs. Vd) 2 (1-10) Excluding bortezomib refractory;
previous daratumumab,
allogeneic SCT
ASCT: 61%; bortezomib: 66%;
carﬁlzomib: 4%; dexamethasone:
91%; lenalidomide: 42%;
thalidomide: 49%
PI refractory: 1%; IMiD refractory:
33%; PI and IMiD refractory: 3%;
bortezomib refractory: 0.6%;
carﬁlzomib refractory: 2%; ixazomib
refractory: 2%; lenalidomide
refractory: 28%; pomalidomide
refractory: 3%; thalidomide
refractory: 11%
ENDEAVOR (Kd vs. Vd) 2 (1-4) Excluding bortezomib or
carﬁlzomib refractory
Bortezomib: 54%; carﬁlzomib:
< 1%; lenalidomide: 38%;
thalidomide: 49%
NR
MMVAR-Velcade
(TVd vs. Vd)
1 previous ASCT:
53%;  2 previous
ASCTs: 47%
Including  1 ASCT; excluding
allogeneic SCT
Bortezomib: 20%-21%;
thalidomide: 6%-10%
NR
Nordic Myeloma Study
(Td vs. Vd)
NR (only required
patients were refractory
to melphalan)
Excluding previous bortezomib,
lenalidomide, thalidomide
High-dose melphalan: 49%-52% NR
PANORAMA 1 (FVd vs. Vd) NR Excluding primary refractory;
bortezomib refractory
Bortezomib: 43%; dexamethasone:
81%; lenalidomide: 20%;
melphalan (oral): 29%;
thalidomide: 51%
NR
VCD Phase III (CVd vs. Vd) NR NR bortezomib: 14% NR
Abbreviations: ASCT ¼ autologous stem cell transplantation; CVd ¼ cyclophosphamide, bortezomib, dexamethasone; DVd ¼ daratumumab, bortezomib, dexamethasone; EVd ¼ elotuzumab,
bortezomib, dexamethasone; FVd ¼ panobinostat, bortezomib, dexamethasone; IMiD ¼ immunomodulatory drug; Kd ¼ carﬁlzomib, dexamethasone; LOT ¼ line of therapy; NMA ¼ network meta-
analysis; NR ¼ not reported; PI ¼ proteasome inhibitor; RCT ¼ randomized controlled trial; SCT ¼ stem cell transplantation; Td ¼ thalidomide, dexamethasone; TVd ¼ thalidomide, bortezomib,
dexamethasone; Vd ¼ bortezomib, dexamethasone.
Supplemental Table 3 Cochrane Library Search Strategy
Search Search Criteria Search Algorithm
Search Yield
(March 17, 2016)
Update Search Yield
(November 3, 2016)
1 1 MeSH descriptor: [Multiple Myeloma] OR MeSH descriptor:
[Plasmacytoma] OR (("multiple" and myelom*) or "plasma cell
myeloma" or "Kahler’s disease" or plasmacytom*):ti,ab,kw
2316 3485
2 2 (relaps* or refract* or recurren* or "resistant" or "prior treatment"
or "prior treatments" or "prior therapy" or "prior therapies" or
"previously treated" or "second line" or "third line" or "2nd line"
or "3rd line" or "fourth line" or "4th line"):ti,ab,kw
70,006 72,334
3 1 & 2 612 613
The limits for this search included only items in the Cochrane Reviews (reviews only), other reviews, trials, and economic evaluations; the Cochrane Library Search Strategy included (1) Cochrane
reviews (reviews only; ie, not including protocols); (2) database of abstracts of reviews of effects (DARE; this has been an archive database only since 2015); (3) the Cochrane Central Register of
Controlled Trials (CENTRAL); (4) National Health Services Economic Evaluation Database (NHS-EED; this has been an archive database only since 2015).
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Supplemental Table 5 Quality Assessment
Assessment Details ASPIRE ELOQUENT-2 POLLUX Tourmaline-MM1 Study
Number of patients randomized Total across groups 792 646 569 722
Was the method of allocation
concealment presented? (yes/no)
The process (ie, central telephone
service, computer-based system
only readable at time of allocation,
opaque and sequenced sealed
envelopes) used to prevent
foreknowledge of which comparison
group an individual will be assigned
to in a RCT
NA (open-label trial) NA (open-label trial) NA (open-label trial) No
How was allocation concealed? If applicable, state methods used for
allocation concealment: central
telephone service, computer-based
system only readable at the time of
allocation, opaque and sequenced
sealed envelopes
NA (open-label trial) NA (open-label trial) NA (open-label trial) NR
Which randomization technique was
used?
Simple (single sequence), block
(into group that results in equal
sample sizes), stratiﬁcation (by
covariates)
Stratiﬁed randomization;
randomization stratiﬁed according
to baseline b2-microglobulin level
(< 2.5 mg/L vs.  2.5 mg/L);
previous therapy with bortezomib
(no vs. yes); previous therapy with
lenalidomide (no vs. yes)
Stratiﬁed randomization;
randomization stratiﬁed according
to baseline b2-microglobulin level
(< 3.5 mg/L vs.  3.5 mg/L);
number of previous therapies
(1 vs. 2 or 3); previous
immunomodulatory drug therapy
(none vs. thalidomide only or other)
Central randomization; randomization
was balanced using randomly
permuted blocks and stratiﬁed
according to ISS (I, II, or III); number
of previous lines of therapy
(1 vs. 2 or 3 vs. > 3); previous
lenalidomide treatment (no vs. yes)
Stratiﬁed randomization; randomization
was stratiﬁed according to number
of previous treatment lines (1 vs. 2
or 3); previous exposure to
proteasome inhibitors (no vs. yes);
ISS (I or II vs. III)
Was a justiﬁcation of the
sample size provided?
If yes, copy and paste justiﬁcation
provided
Yes: total of 700 subjects enrolled
uniformly over 18-mo period and
followed up for an additional 18 mo
after planned closure of enrollment
expected to result in required 526
events within w36 mo of ﬁrst
randomized subject; a number of
526 events (disease progression or
death) required to provide 90%
power to detect a 25% reduction in
risk of disease progression or death
(HR, 0.75) at 1-sided signiﬁcance
level of 0.025
Yes: it was determined that 640
patients with 466 events would
provide a power of 89% to detect
an HR of 0.74 for disease
progression or death in the
elotuzumab group in the
ﬁnal analysis
Yes: total of 295 PFS events
provided 85% power (2-sided
a¼0.05) to detect improvement
of 7.7 mo in median PFS
(Rd, 18 mo; DRd, 25.7 mo); with
a 16-mo accrual and 18-mo
follow-up, 560 subjects needed
Yes: total sample size was calculated
such that the study would have
80% power to detect a 30%
difference in OS (HR, 0.70), at a
2-sided a level of 0.05; study was
powered to detect the superiority of
intervention over placebo
Was follow-up adequate? Report latest time point of follow-up
results (1-, 2-, 3-year and/or median
follow-up) and whether this was
interim or ﬁnal and/or if additional
updated analyses are planned
Median follow-up: 32.3 mo; interim
analysis for PFS
Minimum follow-up: 2 y; ﬁnal
analysis for PFS
Median follow-up: 17.3 mo; interim
analysis for PFS and OS
Median follow-up: 23 mo; interim
analysis for OS
Were all care providers blinded? Was the study open-label, single or
double-blinded? Were those
providing treatment blinded?
No: open-label trial No: open-label trial No: open-label trial Yes: double-blinded study
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Supplemental Table 5 Continued
Assessment Details ASPIRE ELOQUENT-2 POLLUX Tourmaline-MM1 Study
Were all assessors blinded to
treatment allocation?
Was the study open-label, single or
double-blinded? Were those
assessing outcomes blinded? Did
they report outcomes by independent
review committee?
Open-label trial: treatment responses
and disease progression were
assessed centrally in a blinded
manner by an independent review
committee
Open-label trial: treatment responses
and disease progression were
assessed centrally in a blinded
manner by an independent review
committee
Open-label trial; an unblinded
independent data monitoring
committee reviewed safety
data on a regular basis
Unclear: NR whether assessors and
care providers are the same
Was the intent-to-treat population
used?
That is, all those randomized to
treatment included in the efﬁcacy
analyses?
Yes Yes Yes Yes
Were the statistical analyses used
appropriate?
Was it appropriately powered to
detect differences?
Yes: a number of 526 events
(disease progression or death) were
required to provide 90% power to
detect a 25% reduction in risk of
disease progression or death
(HR, 0.75) at a 1-sided signiﬁcance
level of 0.025
Yes: it was determined that
640 patients with 466 events
would provide a power of 89% to
detect an HR of 0.74 for disease
progression or death in the
elotuzumab group in the ﬁnal
analysis; the a level for the analysis
of PFS (0.0239) was calculated
according to occurrence of 384 of
466 events (82%) at the interim
analysis
Yes: a total of 295 PFS events
provided 85% power (2-sided
a¼0.05) to detect improvement
of 7.7 mo in median PFS (Rd,
18 mo; DRd, 25.7 mo); with
16-mo accrual and 18-mo
follow-up, 560 subjects needed
Yes: total sample size was
calculated such that the study would
have 80% power to detect a 30%
difference in OS (HR, 0.70) at a
2-sided a level of 0.05; the study
was powered to detect the superiority
of intervention over placebo
Did the safety analysis include all
patients that received  1 dose?
Yes: all subjects who received
at  1 dose of any study-speciﬁc
treatment were included in the
safety analysis
Yes: exposure and safety were
analyzed for all randomized patients
who had received  1 dose of any
study medication (all treated patients)
Yes: subjects who received  1
administration of any study
treatment used for all safety analyses
Yes: the safety population included
all patients who had received 
1 dose of a study drug or placebo
For studies with crossover, did they
use rank-preserving structural failure
time model?
NA NA NA NA
For studies with crossover, did they
use the inverse probability of
censoring weighting model per
protocol analyses?
NA NA NA NA
Were all groups similar at baseline
in terms of prognostic factors?
Any differences at baseline? Unclear: P value NR; study protocol
reported the 2 groups were well
balanced at baseline without
further information
Unclear: P value NR; study
reported that baseline characteristics
were balanced between
2 study groups
Unclear: P value NR; study
stated that the 2 treatment groups
were generally well balanced in
baseline disease characteristics
Unclear: P value NR; study reported
that the 2 groups were well balanced
Were any confounding factors
present that might attenuate the
interpretation of the results of the
RCTs?
High-risk patients/cytogenetic
abnormalities
Yes (high, standard cytogenetic risk) No No Yes (standard, high)
Previous line of therapy Yes (1,  2) Yes (1, 2, 3) Yes (1, 2, 3,  3) Yes (1, 2, 3)
Type of previous therapy Yes (bortezomib, lenalidomide) Yes (bortezomib, lenalidomide) Yes (lenalidomide) No
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Supplemental Table 6 Extracted Data From RCTs Included in Base-case Analyses
Study (Comparison) PFS (HR; 95% CI) OS (HR; 95% CI) ORR (OR; P Value)
ASPIRE15 (KRd vs. Rd) 0.69 (0.57-0.83) 0.79 (0.63-0.99) 87.1 vs. 66.7 (< 0.001)
ELOQUENT-217 (ERd vs. Rd) 0.70 (0.57-0.85) 0.77 (0.61-0.97) 1.9 (1.4-2.8; < 0.001)
POLLUX16 (DRd vs. Rd) 0.37 (0.28-0.50) 0.63 (0.42-0.95) 93 vs. 76 (< 0.0001)
Tourmaline-MM118 (NRd vs. Rd) 0.742 (0.587-0.939) 0.905 (0.62-1.32) 78.3 vs. 71.5 (0.035)
Abbreviations: CI ¼ conﬁdence interval; DRd ¼ daratumumab, lenalidomide, dexamethasone; ERd ¼ elotuzumab, lenalidomide, dexamethasone; HR ¼ hazard ratio; KRd ¼ carﬁlzomib, lenalidomide, dexamethasone; NRd ¼ ixazomib, lenalidomide, dexamethasone; OR ¼ odds
ratio; ORR ¼ overall response rate; OS ¼ overall survival; PFS ¼ progression-free survival; RCT ¼ randomized controlled trial; Rd ¼ lenalidomide, dexamethasone.
Supplemental Table 5 Continued
Assessment Details ASPIRE ELOQUENT-2 POLLUX Tourmaline-MM1 Study
ISS stage/ECOG status, etc. No Yes: ISS (I, II, III) Yes: ISS (I, II, III); ECOG performance
score (0, 1)
Yes: ISS (I, II, III)
Was the RCT conducted in the UK? Yes, no? No: international: North America,
Europe, and Middle East
No: international: North America
(US, Canada, Mexico, Puerto Rico),
Europe, Japan, rest of world
No: international: North America (US,
Canada), Europe, Russia, Australia,
Israel, Korea
No: international
Are dosage regimens within those
cited in the summaries of product
characteristics?
Available at: https://www.medicines.
org.uk/emc/
Yes: unable to ﬁnd dexamethasone
40 mg in electronic Medicines
Compendium
Yes: unable to ﬁnd elotuzumab
10 mg in electronic Medicines
Compendium
Yes: unable to ﬁnd dexamethasone
40 mg in electronic Medicines
Compendium
Yes: unable to ﬁnd ixazomib
4 mg in electronic Medicines
Compendium
Overall quality score Based on information above, was
the trial of high (þþ), moderate
(þ), or low () quality?
Moderate Moderate Moderate Moderate
Abbreviations: DRd ¼ daratumumab, lenalidomide, dexamethasone; ECOG ¼ Eastern Cooperative Oncology Group; HR ¼ hazard ratio; ISS ¼ International Staging System; NA ¼ not applicable; NR ¼ not reported; OS ¼ overall survival; PFS ¼ progression-free survival;
RCT ¼ randomized controlled trial; Rd ¼ lenalidomide, dexamethasone.
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Supplemental Table 8 Sensitivity Analyses: OS Results
Treatment d Rd Id KRd ERd NRd ICd
DRd 0.34a (0.21, 0.56) 100% 0.63a (0.42, 0.95) 98.7% 0.37a (0.27, 0.82) 99.6% 0.80b (0.50, 1.27) 82.9% 0.82 (0.51, 1.31) 80.0% 0.70b (0.42, 1.16) 91.9% 0.88 (0.34, 2.28) 60.8%
ICd 0.39a (0.17, 0.88); 98.9% 0.72b (0.31, 1.70); 77.5% 0.54b (0.25, 1.17); 94.1% 0.91 (0.37, 2.20); 58.2% 0.93 (0.39, 2.27); 56.0% 0.80b (0.32, 1.97); 69.0% NA
NRd 0.49a (0.33, 0.73); 100% 0.90 (0.67, 1.22); 74.5% 0.68b (0.41, 1.10); 94.5% 1.14 (0.78, 1.67); 24.0% 1.17 (0.80, 1.72); 20.6% NA NA
ERd 0.42a (0.29, 0.60); 100% 0.77a (0.61, 0.97); 98.6% 0.58a (0.37, 0.89); 99.4% 0.98 (0.71, 1.35); 55.9% NA NA NA
KRd 0.43a (0.30, 0.61); 100% 0.79a (0.63, 0.99); 98.0% 0.59a (0.38, 0.92); 99.1% NA NA NA NA
Id 0.72a (0.56, 0.93); 99.6% 1.33 (0.92, 1.92); 6.3% NA NA NA NA NA
Rd 0.54a (0.41, 0.71); 100% NA NA NA NA NA NA
Data presented as HR (95% conﬁdence interval); probability (it is possible that 100% probability will appear to represent any value > 99.951%).
Comparisons presented for each treatment versus each other treatment; speciﬁcally, every combination of A versus B, where A is the treatment at the beginning of each row and B is the treatment at the top of each column; HRs < 1 indicate a numerical advantage for the
treatment at the end of the row. To obtain HRs for comparisons in the opposite direction, reciprocals should be taken. The probability that the HR for A versus B is < 1 (ie, that regimen A is more efﬁcacious) is under the HR.
Abbreviations: d ¼ dexamethasone; DRd ¼ daratumumab, lenalidomide, dexamethasone; ERd ¼ elotuzumab, lenalidomide, dexamethasone; HR ¼ hazard ratio; ICd ¼ pomalidomide, cyclophosphamide, dexamethasone; Id ¼ pomalidomide, dexamethasone; KRd ¼ carﬁlzomib,
lenalidomide, dexamethasone; NA ¼ not applicable; NRd ¼ ixazomib, lenalidomide, dexamethasone; OS ¼ overall survival; Rd ¼ lenalidomide, dexamethasone.
aInterventions with a signiﬁcant advantage.
bInterventions with a trend toward improving OS (eg, HR < 0.80 but credible intervals crossing 1.0).
Supplemental Table 7 Sensitivity Analyses: PFS Results
Treatment d Rd Id KRd ERd NRd ICd
DRd 0.13a (0.09-0.18); 100% 0.37a (0.27-0.51); 100% 0.27a (0.18-0.41); 100% 0.54a (0.37-0.78); 100% 0.54a (0.38-0.80); 99.9% 0.50a (0.33-0.75); 100% 0.41a (0.21-0.79); 99.6%
ICd 0.32a (0.18-0.55); 100% 0.91 (0.51-1.60); 63.5% 0.66b (0.40-1.09); 94.6% 1.31 (0.72-2.39); 18.5% 1.33 (0.73-2.43); 17.6% 1.22 (0.66-2.26); 26.3% NA
NRd 0.26a (0.20-0.34); 100% 0.74a (0.59-0.94); 99.4% 0.54a (0.38-0.76); 100% 1.07 (0.79-1.45); 31.7% 1.09 (0.80-1.49); 29.3% NA NA
ERd 0.24a (0.19-0.30); 100% 0.68a (0.56-0.83); 100% 0.50a (0.36-0.68); 100% 0.99 (0.75-1.30); 54.1% NA NA NA
KRd 0.24a (0.19-0.30); 100% 0.69a (0.57-0.83); 100% 0.50a (0.37-0.69); 100% NA NA NA NA
Id 0.48a (0.39-0.60); 100% 1.37 (1.07-1.77); 0.60% NA NA NA NA NA
Rd 0.35a (0.31-0.40); 100% NA NA NA NA NA NA
Data presented as HR (95% conﬁdence interval); probability (it is possible that 100% probability will appear to represent any value > 99.951%).
Comparisons presented for each treatment versus each other treatment; speciﬁcally, every combination of A versus B, where A is the treatment at the beginning of each row and B is the treatment at the top of each column; HRs < 1 indicate a numerical advantage for the
treatment at the end of the row. To obtain HRs for comparisons in the opposite direction, reciprocals should be taken. The probability that the HR for A versus B is < 1 (ie, that regimen A is more efﬁcacious) is under the HR.
Abbreviations: d ¼ dexamethasone; DRd ¼ daratumumab, lenalidomide, dexamethasone; ERd ¼ elotuzumab, lenalidomide, dexamethasone; HR ¼ hazard ratio; ICd ¼ pomalidomide, cyclophosphamide, dexamethasone; Id ¼ pomalidomide, dexamethasone; KRd ¼ carﬁlzomib,
lenalidomide, dexamethasone; NA ¼ not applicable; NRd ¼ ixazomib, lenalidomide, dexamethasone; PFS ¼ progression-free survival; Rd ¼ lenalidomide, dexamethasone.
aInterventions with a signiﬁcant advantage.
bInterventions with a trend toward improving PFS (eg, HR < 0.80 but credible intervals crossing 1.0).
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